Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus MEDROL.
BREO ELLIPTA vs MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines (e.g., IL-1, IL-2, TNF-alpha). It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
4 to 48 mg orally once daily or every other day, depending on condition. Initial dose may be up to 48 mg/day.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal half-life of methylprednisolone is 2.5-3.5 hours; for the active metabolite (prednisolone), half-life is 2.1-3.5 hours. Clinical context: Despite short half-life, pharmacodynamic effects persist beyond plasma presence due to receptor-mediated actions.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (approximately 80-90% as metabolites, <5% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid